GENFIT: Outcome of the Ordinary and Extraordinary Shareholders’ Meeting of November 27, 2019
28 Novembre 2019 - 06:00PM
GENFIT: Outcome of the Ordinary and Extraordinary Shareholders’
Meeting of November 27, 2019
GENFIT: Outcome of the Ordinary and
Extraordinary Shareholders’ Meeting of November 27,
2019
Lille (France), Cambridge
(Massachusetts, United States), November 28, 2019
– GENFIT (Nasdaq and Euronext: GNFT), a late-stage
biopharmaceutical company dedicated to the discovery and
development of innovative therapeutic and diagnostic solutions in
metabolic and liver related diseases, today announced the results
of the voting by shareholders at the Ordinary and Extraordinary
Shareholders’ Meeting which took place on November 27, 2019 at the
Company’s headquarters.
All of the resolutions were adopted by a large
majority of at least 78% of the votes cast, except for resolution
n°10 related to issuing ordinary shares and/or securities giving
access to the share capital of the Company for the benefit of the
members of a company savings plan which was rejected, in accordance
with the Board of Directors' recommendations.
9,708,113 shares participated out of a total of
38,802,238 shares with voting rights, representing a quorum of
25.01%.
The details on voting resolution by resolution
are available on the Company’s website, in the investor’s room at
https://ir.genfit.com/financial-information/shareholders-meeting.
ABOUT GENFIT
GENFIT is a late-stage biopharmaceutical company
dedicated to the discovery and development of innovative
therapeutic and diagnostic solutions in metabolic and liver related
diseases where there are considerable unmet medical needs,
corresponding to a lack of approved treatments. GENFIT is a leader
in the field of nuclear receptor-based drug discovery, with a rich
history and strong scientific heritage spanning almost two decades.
Its most advanced drug candidate, elafibranor, is currently being
evaluated in a pivotal Phase 3 clinical trial (“RESOLVE-IT”) as a
potential treatment for NASH, and GENFIT plans to initiate a Phase
3 clinical trial of elafibranor in PBC in 2020, following its
positive Phase 2 results. As part of GENFIT’s comprehensive
approach to clinical management of patients with NASH, the company
is also developing a new, non-invasive blood-based diagnostic test,
NIS4, which, if approved, could enable easier identification of
patients with NASH. With facilities in Lille and Paris, France, and
Cambridge, MA, USA, the Company has approximately 200 employees.
GENFIT is a publicly traded company listed on the Nasdaq Global
Select Market and in compartment B of Euronext’s regulated market
in Paris (Nasdaq and Euronext: GNFT). www.genfit.com
CONTACT
GENFIT | Investors
Naomi EICHENBAUM – Investor Relations | Tel: +1
(617) 714 5252 | investors@genfit.com
PRESS RELATIONS | Media
Hélène LAVIN – Press relations | Tel: +333 2016
4000 | helene.lavin@genfit.com
GENFIT | 885 Avenue Eugène Avinée, 59120 Loos -
FRANCE | +333 2016 4000 |
www.genfit.com
- GENFIT: Outcome of the Ordinary and Extraordinary Shareholders’
Meeting of November 27, 2019
Grafico Azioni Genfit (EU:GNFT)
Storico
Da Feb 2024 a Mar 2024
Grafico Azioni Genfit (EU:GNFT)
Storico
Da Mar 2023 a Mar 2024